Pharmacogenetic information in Swiss drug labels – a systematic analysis
Authors:
Open Access
- 17 October 2020
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 21 (4) , 423-434
Abstract
Implementation of pharmacogenetics (PGx) and individualization of drug therapy is supposed to obviate adverse drug reactions or therapy failure. Health care professionals (HCPs) use drug labels (DLs) as reliable information about drugs. We analyzed the Swiss DLs to give an overview on the currently available PGx instructions. We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB. From 5979 hits, 2564 were classified as PGx-relevant affecting 167 substances. 55% (n = 93) were classified as “actionable PGx”. Frequently, PGx information appeared in the pharmacokinetics section and in DLs of the anatomic group “nervous system”. Unstandardized wording, appearance of PGx information in different sections and unclear instructions challenge HCPs to identify and interpret PGx information and translate it into practice. HCPs need harmonization and standardization of PGx information in DLs to personalize drug therapies and tailor pharmaceutical care.Keywords
This publication has 42 references indexed in Scilit:
- The Role of Platelet Reactivity and Genotype Testing in the Prevention of Atherothrombotic Cardiovascular Events Remains UnprovenCirculation, 2012
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) GenotypeClinical Pharmacology & Therapeutics, 2011
- Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in TaiwanNew England Journal of Medicine, 2011
- HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in EuropeansNew England Journal of Medicine, 2011
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyNew England Journal of Medicine, 2008
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugsThe Pharmacogenomics Journal, 2004
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- VARIANTS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASEAnnals of the New York Academy of Sciences, 1971